“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in NOK
Last close As at 09/06/2023
NOK82.40
▲ −34.60 (−29.57%)
Market capitalisation
NOK2,834m
Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.
Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.
Managing Director - Head of Content, Healthcare
Carlos de Sousa
CEO
Gustav Gaudernack
CSO
Hans Vassgård Eid
CFO
Jens Bjørheim
CMO
Ton Berkien
CBO
Forecast net cash (NOKm)
346.1
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (35.0) | (27.0) | 10.8 |
| Relative | (35.0) | (23.5) | 20.7 |
| 52 week high/low | NOK136.0/NOK59.9 |
Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential. Lead asset, UV1, activates the immune system to recognise cancer cells that express hTERT, which is present in c 85% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The broad R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total. Readouts are expected over 2023–25. The most near-term catalysts for the share price are top-line readouts from the Phase II NIPU trial in pleural mesothelioma and the Phase II INITIUM study in malignant melanoma expected in H123 and H223, respectively.
| Y/E Dec | Revenue (NOKm) | EBITDA (NOKm) | PBT (NOKm) | EPS (fd) (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.0 | (161.1) | (164.7) | (508.83) | N/A | N/A |
| 2022A | 0.0 | (181.0) | (167.8) | (489.06) | N/A | N/A |
| 2023E | 0.0 | (222.7) | (210.8) | (612.84) | N/A | N/A |
| 2024E | 0.0 | (274.0) | (277.9) | (807.97) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
